Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Adam on +441494 818 010 or adam@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Adam Woolley
Recruitment Consultant
adam@zenopa.com
+441494 818 010

Testimonials
I would just like to say thank you so much for your help recently in finding my next job. Can't wait to start.
Ian, 2011

Novartis data highlights benefits of individualised Lucentis

5 September 2012 11:40 in Pharmaceutical Company Product News


Novartis has announced new clinical data showing that its anti-VEGF therapy Lucentis can provide sustained improvement in vision with a low number of injections, when applied using an individualised treatment regimen.

Results from the Repair study shows that an average of three Lucentis injections, administered on an individualised basis, can improve visual acuity in patients with myopic choroidal neovascularisation.

Meanwhile, data from the Restore extension study showed that individualised Lucentis can deliver maintained vision gains for diabetic macular oedema patients over three years.

Novartis is also currently carrying out a five-year trial called Luminous, which aims to assess long-term evidence on the real-world effectiveness and safety profile, and currently has more than 5,500 patients enrolled.

Tim Wright, global head of development at Novartis Pharma, said: "This new data confirms that an individualised treatment approach can lead to optimal improvements in vision with a low average number of treatments, thus ensuring that patients with retinal diseases are not over or under-treated."

Last week, the company also published positive clinical trial data for QVA149, an investigational therapy it is developing for chronic obstructive pulmonary disease.ADNFCR-8000103-ID-801442720-ADNFCR

Other news stories from 05/09/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd